Clinical Trial

Clinical Trial to Evaluate the Pharmacokinetics and Safety Between the Single Administration of HL1113 and the Concomitant Administration of HL1113R1 and HL1113R2 for Healthy Subjects in Fasting State

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial is a randomized, open-label, single oral dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the single administration of HL1113 and the concomitant administration of HL1113R1 and HL1113R2 for healthy subjects in fasting state
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-28.
Trial Details
NCT Number NCT07568652
Lead Sponsor Hanlim Pharm. Co., Ltd.
Conditions Hypertension, Diabete Type 2
Enrollment 37 participants
Start Date 2024-10-16
Primary Completion 2024-11-15 (estimated)
Study Completion 2024-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-18